

# Learner Notification

---

## Anticoagulation Forum

### Lessons Learned from DOAC Claims-based Observational Studies

Date of CE Release: 02-24-2022

Date of CE Expiration: 02-24-2024

Location: Online

### **Acknowledgement of Financial Commercial Support**

No financial commercial support was received for this educational activity.

### **Acknowledgement of In-Kind Commercial Support**

No in-kind commercial support was received for this educational activity.

### **Satisfactory Completion**

Learners must listen to each self-directed audio recording while following along with the visual slides/read the articles, and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### **Joint Accreditation Statement**



In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Anticoagulation Forum. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### **Physicians**

Amedco LLC designates this material for a maximum of 1.0 *AMA PRA Category 1 Credits™* for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### **Pharmacists and Pharmacy Technicians**

Amedco LLC designates this activity for a maximum of 1.0 knowledge-based CPE contact hours.

### **Nurses**

Amedco LLC designates this activity for a maximum of 1.0 ANCC contact hours.

### **Objectives - After Attending This Program You Should Be Able To**

1. Compare and contrast the relative rates of major ischemic and hemorrhagic events observed in a large retrospective cohort study of apixaban and rivaroxaban in patients with atrial fibrillation
2. Recognize the inherent limitations of observational studies and consider possible biases and confounding factors that may

have contributed to the findings

3. Discuss differences in pharmacokinetic and pharmacodynamic properties of apixaban and rivaroxaban and how these differences may have contributed to the study's findings

## Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5)

All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

Name	Commercial Interest:Relationship
Geoff Barnes	Pfizer/Bristol-Myers Squibb, Janssen, Portola, AMAG Pharmaceuticals:Consultant Anticoagulation Forum, National Certification Board of Anticoagulation Providers:Scientific/Medical Advisory Board Member
Katherine Murray	Metabolic Technologies Inc:Other
Wayne Ray	NA
Deborah Siegal	BMS-Pfizer, Leo Pharma, Portola Pharmaceuticals, Servier:Other

## How to Get Your Certificate

1. Go to <http://acf.cmecertificateonline.com>
2. Click on the **Lessons Learned from DOAC Claims-based Observational Studies** link.
3. Evaluate the meeting.
4. Print, download, or save your certificate for your records.